Anxiety Disorders and Depression Treatment Market is projected to reach US$18.2 billion by 2020

The Global anxiety disorders and depression treatment market will demonstrate a mediocre CAGR of 1.25% during the forecast period of 2014 to 2020. In 2013, the global anxiety disorders and depression treatment market stood at US$22.5 billion in 2013 and is projected to reach US$18.2 billion by 2020.According to WHO, currently an estimated 350 million people globally are affected with depression. The primary driver of the global anxiety disorders and depression treatment market is the accelerating prevalence of depression and anxiety disorders. Other factors driving the global anxiety disorders and depression treatment market are rising geriatric population and increasing efficacy and decreasing side effects of drugs in several classes. Nevertheless, the market will decline due to the patent expiry of major antidepressant drugs, weak pipeline of novel drugs, and the rising number of generic drug variants. Furthermore, the drug resistant-mental disorders are likely to challenge the growth of the global anxiety disorders and depression treatment market.

 

By drug class, the global anxiety disorders and depression treatment market is segmented into selective serotonin reuptake inhibitors (SSRIs), anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), beta-blockers, atypical antipsychotics, benzodiazepines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and tetracyclic antidepressants (TeCAs). SNRIs was the leading segment in the global anxiety disorders and depression treatment market in 2013 and held a market share of more than 30%. However, the SNRIs segment will experience decline in the coming few years.Some of the top pipeline drugs anticipated to be launched in the global anxiety disorders and depression treatment market during the forecast period are Brintellix [(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], ALKS-5461 [(FDC-buprenorphine and samidorphan) (Alkermes plc)], and Brexpiprazole [(OPC-34712) (Otsuka)].

 

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

 

By geography, the global anxiety disorders and depression treatment market is divided into Europe, Rest of the World (RoW), North America, and Asia Pacific. North America was the global leader in the anxiety disorders and depression treatment market. This segment dominated the market due to the presence of its large patient population affected with several types of anxiety disorders and depression. At present, the U.S. anxiety disorders and depression treatment market is saturated as various antidepressant drugs are available on prescription for the same symptom. Thus, the growth of this market will rely on introduction of more effective drugs for new symptoms. On the other hand, Asia Pacific will demonstrate a moderate growth due to presence of emerging countries such as Japan, China, and Australia.

 

Players in the market will benefit from the improving distribution network in budding economies along with the development of herbal remedies. The key players operating in the global anxiety disorders and depression treatment market are AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories, H. Lundbeck, Merck & Co., and Johnson & Johnson.

 

Browse the full Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html